| NMDAR inhibition-independent antidepressant actions of ketamine metabolites P Zanos, R Moaddel, PJ Morris, P Georgiou, J Fischell, GI Elmer, ... Nature 533 (7604), 481-486, 2016 | 1471 | 2016 |
| Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms P Zanos, R Moaddel, PJ Morris, LM Riggs, JN Highland, P Georgiou, ... Pharmacological reviews 70 (3), 621-660, 2018 | 933 | 2018 |
| Mechanisms of ketamine action as an antidepressant P Zanos, TD Gould Molecular psychiatry 23 (4), 801-811, 2018 | 833 | 2018 |
| Convergent mechanisms underlying rapid antidepressant action P Zanos, SM Thompson, RS Duman, CA Zarate, TD Gould CNS drugs 32, 197-227, 2018 | 168 | 2018 |
| Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function EW Lumsden, TA Troppoli, SJ Myers, P Zanos, Y Aracava, J Kehr, J Lovett, ... Proceedings of the National Academy of Sciences 116 (11), 5160-5169, 2019 | 150 | 2019 |
| The oxytocin analogue carbetocin prevents emotional impairment and stress-induced reinstatement of opioid-seeking in morphine-abstinent mice P Zanos, P Georgiou, SR Wright, SM Hourani, I Kitchen, ... Neuropsychopharmacology 39 (4), 855-865, 2014 | 137 | 2014 |
| (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions P Zanos, JN Highland, BW Stewart, P Georgiou, CE Jenne, J Lovett, ... Proceedings of the National Academy of Sciences 116 (13), 6441-6450, 2019 | 134 | 2019 |
| Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters A Can, P Zanos, R Moaddel, HJ Kang, KSS Dossou, IW Wainer, JF Cheer, ... Journal of Pharmacology and Experimental Therapeutics 359 (1), 159-170, 2016 | 118 | 2016 |
| The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineB-site inhibition P Zanos, SC Piantadosi, HQ Wu, HJ Pribut, MJ Dell, A Can, ... Journal of Pharmacology and Experimental Therapeutics 355 (1), 76-85, 2015 | 106 | 2015 |
| A negative allosteric modulator for alpha5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA … P Zanos, ME Nelson, JN Highland, SR Krimmel, P Georgiou, TD Gould, ... eneuro, 2017 | 100 | 2017 |
| Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites PJ Morris, R Moaddel, P Zanos, CE Moore, T Gould, CA Zarate Jr, ... Organic letters 19 (17), 4572-4575, 2017 | 88 | 2017 |
| Animal models to improve our understanding and treatment of suicidal behavior TD Gould, P Georgiou, LA Brenner, L Brundin, A Can, P Courtet, ... Translational psychiatry 7 (4), e1092-e1092, 2017 | 87 | 2017 |
| (R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses P Zanos, JN Highland, X Liu, TA Troppoli, P Georgiou, J Lovett, PJ Morris, ... British journal of pharmacology 176 (14), 2573-2592, 2019 | 74 | 2019 |
| Experimenters’ sex modulates mouse behaviors and neural responses to ketamine via corticotropin releasing factor P Georgiou, P Zanos, TCM Mou, X An, DM Gerhard, DI Dryanovski, ... Nature neuroscience 25 (9), 1191-1200, 2022 | 67 | 2022 |
| Dopamine and stress system modulation of sex differences in decision making P Georgiou, P Zanos, S Bhat, JK Tracy, IJ Merchenthaler, MM McCarthy, ... Neuropsychopharmacology 43 (2), 313-324, 2018 | 67 | 2018 |
| Chronic methamphetamine treatment induces oxytocin receptor up-regulation in the amygdala and hypothalamus via an adenosine A2A receptor-independent mechanism P Zanos, SR Wright, P Georgiou, JH Yoo, C Ledent, SM Hourani, I Kitchen, ... Pharmacology Biochemistry and Behavior 119, 72-79, 2014 | 63 | 2014 |
| Hydroxynorketamines: pharmacology and potential therapeutic applications JN Highland, P Zanos, LM Riggs, P Georgiou, SM Clark, PJ Morris, ... Pharmacological reviews 73 (2), 763-791, 2021 | 62 | 2021 |
| Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine JN Highland, PJ Morris, P Zanos, J Lovett, S Ghosh, AQ Wang, ... Journal of Psychopharmacology 33 (1), 12-24, 2019 | 57 | 2019 |
| Oxytocin and opioid addiction revisited: old drug, new applications P Zanos, P Georgiou, C Weber, F Robinson, C Kouimtsidis, ... British journal of pharmacology 175 (14), 2809-2824, 2018 | 52 | 2018 |
| Methamphetamine abstinence induces changes in μ-opioid receptor, oxytocin and CRF systems: Association with an anxiogenic phenotype P Georgiou, P Zanos, JA Garcia-Carmona, S Hourani, I Kitchen, ... Neuropharmacology 105, 520-532, 2016 | 52 | 2016 |
Todd D. GouldUniversity of Maryland School of MedicineVerified email at som.umaryland.edu
